A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma

Miller, Kathy D.; Munshi, Nikhil C.; Loesch, David; Einhorn, Lawrence H.; Sledge, George W.

doi:10.1002/(sici)1097-0142(20000115)88:2<375::aid-cncr19>3.0.co;2-m

Cited by 6 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy for metastatic brain tumours from breast cancer has been performed using cyclophosphamide, 5-fluorpuracil, methothorexiate, vincristin, and adriamycine, alone or in combination 10 . Recently, Epirubicine (Farmorbicine) has become available with or without other drugs followed by hormone therapy using medroxyprogesterone [11][12][13] .…”

Section: Discussionmentioning

confidence: 99%

Superselective Arterial Chemotherapy for Inoperable Metastases in the Dura Mater and Cranium

Suzuki¹,

Kurata²,

Nakahara³

et al. 2002

Interv Neuroradiol

View full text Add to dashboard Cite

Diffuse metastases to the cranium and dura mater of the bilateral hemisphere do not allow surgical intervention. We describe an excellent case which was treated by intra-arterial chemotherapy using Epirubicine (Farumorbicine). A 58-year-old woman treated for breast cancer ten years ago was admitted to our hospital with headache and frontal mass lesions. Magnetic resonance (MR) imaging on admission revealed a remarkable enhanced lesion of the bilateral dura mater and cranium, and bilateral brain edema in the frontal lobe. Angiography disclosed a vascular rich tumour supplied by bilateral external carotid artery branches. We successfully treated the lesion using superselective intra-arterial chemotherapy with a minimal dose of Epirubicine followed by embolization of bilateral external carotid artery branches. Follow-up MR imaging two years after the endovascular treatment showed disappearance of the enhanced lesion and remodeling of the skull bone. The patient is neurologically free of symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Superselective Arterial Chemotherapy for Inoperable Metastases in the Dura Mater and Cranium

Suzuki¹,

Kurata²,

Nakahara³

et al. 2002

Interv Neuroradiol

View full text Add to dashboard Cite

show abstract

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

et al. 2016

View full text Add to dashboard Cite

Controlling effects of drugs administered in combination is particularly challenging with a densified regimen because of life-threatening hematological toxicities. We have developed a mathematical model to optimize drug dosing regimens and to redesign the dose intensification-dose escalation process, using densified cycles of combined anticancer drugs. A generic mathematical model was developed to describe the main components of the real process, including pharmacokinetics, safety and efficacy pharmacodynamics, and non-hematological toxicity risk. This model allowed for computing the distribution of the total drug amount of each drug in combination, for each escalation dose level, in order to minimize the average tumor mass for each cycle. This was achieved while complying with absolute neutrophil count clinical constraints and without exceeding a fixed risk of non-hematological dose-limiting toxicity. The innovative part of this work was the development of densifying and intensifying designs in a unified procedure. This model enabled us to determine the appropriate regimen in a pilot phase I/II study in metastatic breast patients for a 2-week-cycle treatment of docetaxel plus epirubicin doublet, and to propose a new dose-ranging process. In addition to the present application, this method can be further used to achieve optimization of any combination therapy, thus improving the efficacy versus toxicity balance of such a regimen.

show abstract

Cytostatic drugs

Fraser¹,

Twelves²,

Stanley³

2002

Side Effects of Drugs Annual

View full text Add to dashboard Cite

A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma

Cited by 6 publications

References 25 publications

Superselective Arterial Chemotherapy for Inoperable Metastases in the Dura Mater and Cranium

Superselective Arterial Chemotherapy for Inoperable Metastases in the Dura Mater and Cranium

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

Cytostatic drugs

Contact Info

Product

Resources

About